Elanco Animal Health (NYSE:ELAN) Releases Earnings Results, Beats Expectations By $0.06 EPS

06 May 2026, 18:48 by Renee Jackson · The Cerbat Gem

Elanco Animal Health (NYSE:ELAN – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.34 by $0.06, FiscalAI reports. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same period last year, the firm earned $0.37 EPS. The company’s revenue was up 14.9% on a year-over-year basis. Elanco Animal Health updated its Q2 2026 guidance to 0.250-0.285 EPS and its FY 2026 guidance to 1.030-1.090 EPS.

Here are the key takeaways from Elanco Animal Health’s conference call:

Raised guidance: Elanco increased full-year targets to 5%-7% organic growth, adjusted EBITDA of $975M–$1.005B, adjusted EPS of $1.03–$1.09, and raised its 2026 innovation revenue goal to $1.2B.
Launch momentum: Innovation sales drove the quarter — Zenrelia reached blockbuster status and is now in >50% of U.S. clinics with >80% reorder rates, while Credelio Quattro is in >40% of clinics and has reached 53% share within those clinics, with rapid international rollout underway.
Strong Q1 financials and deleveraging: Q1 revenue of $1.371B (10% organic growth) produced adjusted EBITDA of $334M (+21%) and EPS of $0.40, with net debt $3.3B (3.5x) and management tightening year-end net leverage guidance to 3.0–3.2x and targeting
Key risks: The FDA has requested additional data for Zenrelia (company’s guidance assumes no U.S. label change), and management flagged near-term gross margin headwinds from inventory/inflation plus competitive/generic pressures that could push results toward the low end of guidance.
Productivity program: The Elanco Ascend initiative (5,000+ projects) plus AI/automation is expected to drive margin expansion and operational efficiencies, enabling continued reinvestment in launches and a target of >$1B free cash flow through 2028.

Elanco Animal Health Price Performance

Shares of ELAN traded up $3.22 during midday trading on Wednesday, hitting $26.21. 12,364,331 shares of the company traded hands, compared to its average volume of 4,989,493. The stock has a market cap of $13.03 billion, a price-to-earnings ratio of -54.60, a PEG ratio of 2.87 and a beta of 1.69. The firm has a 50 day moving average of $23.82 and a 200-day moving average of $23.29. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. Elanco Animal Health has a 52 week low of $10.75 and a 52 week high of $27.72.

Trending Headlines about Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

Positive Sentiment: Q1 beat on both EPS and revenue — Elanco reported $0.40 EPS vs. consensus $0.34 and revenue of $1.37B (vs. ~$1.28B est.), with revenue up ~15% year‑over‑year. The print is the primary driver of the rally because it showed improving top‑line momentum and margin progression. Elanco Beats Q1 Earnings and Revenue Estimates
Positive Sentiment: Management raised FY‑2026 guidance and innovation targets — Elanco lifted revenue, adjusted EBITDA and adjusted EPS (FY EPS raised to $1.03–$1.09) and improved its year‑end net leverage target, signaling stronger operating leverage and cash‑flow outlook. That upgrade supports a higher valuation multiple for the stock. Elanco Reports Q1 2026 Results and Raises Guidance
Positive Sentiment: Product momentum: two products (Negasunt Powder and Tanidil) received emergency use authorizations, supporting near‑term revenue upside from innovation and validating R&D/launch execution. This likely boosted investor confidence in the growth story. Elanco Moves Higher on Earnings Strength and Product Momentum
Neutral Sentiment: Analyst sentiment is constructive — coverage shows an average rating of “Moderate Buy,” which may support follow‑through buying but doesn’t imply unanimous bullishness. Analysts Give Elanco Moderate Buy Rating
Negative Sentiment: Q2 EPS guidance came in slightly below consensus — Elanco gave Q2 EPS guidance of $0.250–$0.285 versus a street estimate near $0.290, which tempers the beat-and-raise message and could limit upside if investors focus on near‑term cadence rather than full‑year improvement. Q2 Guidance in Elanco Q1 Release

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Morgan Stanley raised their price target on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Leerink Partners increased their target price on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Citigroup assumed coverage on Elanco Animal Health in a report on Wednesday, April 15th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, KeyCorp upped their price target on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.90.

Read Our Latest Stock Analysis on Elanco Animal Health

Institutional Investors Weigh In On Elanco Animal Health

A number of hedge funds have recently made changes to their positions in ELAN. Parallel Advisors LLC grew its holdings in Elanco Animal Health by 5.9% during the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock valued at $160,000 after buying an additional 392 shares in the last quarter. Lazard Asset Management LLC raised its holdings in shares of Elanco Animal Health by 0.6% during the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after acquiring an additional 425 shares in the last quarter. Meeder Advisory Services Inc. raised its holdings in shares of Elanco Animal Health by 4.8% during the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after acquiring an additional 510 shares in the last quarter. NewEdge Advisors LLC boosted its position in shares of Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares during the last quarter. Finally, Arkadios Wealth Advisors grew its holdings in shares of Elanco Animal Health by 1.2% in the fourth quarter. Arkadios Wealth Advisors now owns 52,868 shares of the company’s stock valued at $1,196,000 after purchasing an additional 652 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

About Elanco Animal Health

(Get Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.